GETTING READY FOR YOUR BLUE LIGHT CYSTOSCOPY WITH CYSVIEW®

Patient Name:		Healthca	re Provider Contact Information
Date/Time of Procedure: _	@	AM/PM	
Location:			
	e a Blue-Light Cystoscopy with Cy dicate a condition called nonmuscle		bladder for any abnormal growths or which is a very treatable disease.
Description of pro	ocedure		
50			
A solution is delivered into your bladder an hour before the procedure.	2 During the procedure, a long thin tube called a <i>cystoscope</i> is inserted where urine leaves your body.	3 Doctor looks through the tul with a white light, then a blu light, which makes abnorma cells easier to see and ident	e cells for further testing.
Preparing for you	ır cystoscopy		
The following is important inf	formation you need to know about	your cystoscopy:	
Your test will be performed	in the hospital or clinic operating r	room on an:	
Outpatient basis (you arrive and go home on the same day)		Inpatient basis (you are admitted as a patient to the facility)	
Depending on whether or r the procedure or to have a	not your doctor plans to use anesth light breakfast.	nesia, you may be instructed not	to eat for several hours before
Anesthesia will be used		Anesthesia will not be used	
Patient Instructions:			

- Be sure to tell your healthcare professional all of the medications you are currently taking and ask whether your medications should be taken before or held until after the procedure.
- Approximately 2 ounces of Cysview (hexaminolevulinate HCl) solution will be gradually delivered to your bladder through
 a sterile plastic tube about 1 hour before the procedure.
- Don't be concerned if you can't hold the solution in your bladder; just let your healthcare professional know if this becomes a problem for you.
- Though Blue-Light Cystoscopy with Cysview is considered safe, any procedure may have some risks and you should consult your doctor regarding the risks and benefits of this procedure.
- The most common patient complaints with Cysview include bladder spasm, discomfort when passing urine, frequent urination, blood in the urine, bladder pain, procedural pain, urinary retention, and headache. On rare occasions, patients have experienced increased heart rate, chest pain and fever.



What to expect after the procedure

The following are important things to keep in mind for after your Blue-Light Cystoscopy with Cysview:

- Once the procedure is finished, your bladder will be full of water and it will probably be necessary to pass urine again.
- Most people—including those who have just had local anesthesia—feel ready to go home after a short time; once home, you should plan to rest for the remainder of the day.
- It's not uncommon to have some bladder spasms after a cystoscopy, which can make you feel like you need to go to the bathroom more often than usual.
- You may feel some stinging when you pass urine for a couple of days.
- Blood in the urine is also common for several days after the procedure, particularly if you have had some cancer cells removed.
- In rare cases, patients may have more difficulty passing urine after their cystoscopy; should that happen, a catheter may be left in the bladder to drain excess fluid until any swelling goes down.
- Some patients may develop a mild infection after cystoscopy; this may usually be treated with antibiotics. Consult your
 physician if you are concerned.

Drinking plenty of water can help with many of these issues.

When to seek help from your doctor

After 2 or 3 days if you still have blood in the urine, you see blood clots after you have urinated several times, or if any of your symptoms are severe, please contact your healthcare professional for advice.

Important risk & safety information

Cysview is not a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer.

Anaphylactoid shock, hypersensitivity reactions, bladder pain, cystitis, and abnormal urinalysis have been reported after administration of Cysview. The most common adverse reactions seen in clinical trials were bladder spasm, dysuria, hematuria, and bladder pain.

Cysview should not be used in patients with porphyria, gross hematuria, or with known hypersensitivity to hexaminolevulinate or any derivative of aminolevulinic acid. Cysview may fail to detect some malignant lesions. False positive fluorescence may occur due to inflammation, cystoscopic trauma, scar tissue, previous bladder biopsy and recent BCG therapy or intravesical chemotherapy. No specific drug interaction studies have been performed.

Safety and effectiveness have not been established in pediatric patients. There are no available data on Cysview use in pregnant women. Adequate reproductive and developmental toxicity studies in animals have not been performed. Systemic absorption following administration of Cysview is expected to be minimal. There are no data on the presence of hexaminolevulinate in human or animal milk, the effects on a breastfed infant, or the effects on milk production. The development and health benefits of breastfeeding should be considered along with the mother's clinical need for Cysview and any potential adverse effects on the breastfed infant from Cysview or from the underlying maternal condition.

Cysview is approved for use with the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) system. For system set up and general information for the safe use of the PDD system, please refer to the KARL STORZ instruction manuals for each of the components.

Prior to Cysview administration, read the Full Prescribing Information and follow the preparation and reconstitution instructions.





